Arming antitumor T cells

Arming antitumor T cells

The immune system can only prevent cancer if it recognizes and destroys precancerous cells. Antigenic targets of such an early immune response, however, have been elusive. Spisek et al. (page 831) now find that an embryonic stem cell marker is a bull's eye for immune cells in patients who have precancerous lesions but never develop multiple myeloma. Multiple myeloma is an incurable cancer that ...

Arming NK cells with enhanced antitumor activity

Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laboratory suggest that NK cells may similarly be "armed" against neoplastic cells by the expression of ca...

Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.

T cells ectopically expressing costimulators are pathogenic and contribute to autoimmunity against self-antigens. Given that tumor antigens are often self-antigen or mutated self-antigens, we hypothesize that neoexpressing a costimulator on tumor-reactive T cells may likewise enhance their reactivity to tumor. To test this hypothesis, we have expressed B7-1 on OT-1 CD8+ T-cell receptor transgen...

Arteether Exerts Antitumor Activity and Reduces CD4+CD25+FOXP3+ T-reg Cells in Vivo

Background: Chemo-immunotherapy is one of the new achievements for treatment of cancer, by which the success of anti-cancer therapy can be increased. In vitro studies have been shown that Arteether (ARE) induces apoptosis in tumor cells, but not in normal cells. Objective: To investigate the cytotoxic and immunomodulatory properties of Arteether in-vivo and in-vitro. Methods: In this study, we ...

Dual Control of Antitumor CD8 T Cells